ES2192224T3 - Isotiazolonas. - Google Patents

Isotiazolonas.

Info

Publication number
ES2192224T3
ES2192224T3 ES96913177T ES96913177T ES2192224T3 ES 2192224 T3 ES2192224 T3 ES 2192224T3 ES 96913177 T ES96913177 T ES 96913177T ES 96913177 T ES96913177 T ES 96913177T ES 2192224 T3 ES2192224 T3 ES 2192224T3
Authority
ES
Spain
Prior art keywords
sup
isotiazolones
agents
rent
monociclical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96913177T
Other languages
English (en)
Inventor
Gary Louis Bolton
John Michael Domagala
Edward Faith Elslager
Rocco Dean Gogliotti
Terri Stoeber Purchase
Joseph Peter Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2192224T3 publication Critical patent/ES2192224T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE DESCRIBEN ISOTIAZOLONAS EN QUE POSEEN UNA ESTRUCTURA GENERAL (I) EN LA QUE A ES UN ANILLO MONOCICLICO O BICICLICO QUE PUEDE CONTENER HASTA 3 HETEROATOMOS SELECCIONADOS DE ENTRE O, S Y N; R SUP,1} Y R SUP,2} SON GRUPOS SUSTITUYENTES TALES COMO ALQUILO, ALCOXI, HIDROXI, NITRO, CIANO, AMINO Y CARBOXI; Y R SUP,5} ES UN GRUPO ALQUILO, CICLOALQUILO, FENILO Y HET. LAS ISOTIAZOLONAS SON UTILES COMO AGENTES ANTIRRETROVIRALES, AGENTES ANTIINFLAMATORIOS Y AGENTES ANTIATEROSCLEROTICOS.
ES96913177T 1995-05-31 1996-04-26 Isotiazolonas. Expired - Lifetime ES2192224T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/456,149 US5620997A (en) 1995-05-31 1995-05-31 Isothiazolones

Publications (1)

Publication Number Publication Date
ES2192224T3 true ES2192224T3 (es) 2003-10-01

Family

ID=23811632

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96913177T Expired - Lifetime ES2192224T3 (es) 1995-05-31 1996-04-26 Isotiazolonas.

Country Status (37)

Country Link
US (4) US5620997A (es)
EP (1) EP0828488B1 (es)
JP (1) JP2002502353A (es)
KR (2) KR20040004547A (es)
CN (1) CN1114402C (es)
AR (1) AR002740A1 (es)
AT (1) ATE232385T1 (es)
AU (1) AU723233B2 (es)
BG (1) BG62792B1 (es)
CA (1) CA2218253A1 (es)
CO (1) CO4700292A1 (es)
CZ (1) CZ373997A3 (es)
DE (1) DE69626203T2 (es)
DK (1) DK0828488T3 (es)
EA (1) EA000898B1 (es)
EE (1) EE9700287A (es)
ES (1) ES2192224T3 (es)
GE (1) GEP20012375B (es)
GT (1) GT199600026A (es)
HN (1) HN1996000017A (es)
HR (1) HRP960216B1 (es)
HU (1) HUP9900917A3 (es)
IL (1) IL117859A (es)
MX (1) MX9707948A (es)
MY (1) MY118452A (es)
NO (1) NO975496L (es)
NZ (1) NZ307023A (es)
OA (1) OA10745A (es)
PE (1) PE55097A1 (es)
PL (1) PL323683A1 (es)
PT (1) PT828488E (es)
SK (1) SK162297A3 (es)
SV (2) SV1996000026A (es)
TW (1) TW418206B (es)
UY (1) UY24244A1 (es)
WO (1) WO1996038144A1 (es)
ZA (1) ZA964441B (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001863A (en) * 1996-11-26 1999-12-14 Warner-Lambert Company Isothiazolones
WO1999065871A2 (en) * 1998-06-19 1999-12-23 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Thiolesters and uses thereof
US6706729B1 (en) 1998-06-19 2004-03-16 The United States Of America As Represented By The Department Of Health And Human Services Thiolesters and uses thereof
EE200100155A (et) 1998-09-17 2002-08-15 Bristol-Myers Squibb Company Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
TW591031B (en) * 2000-02-29 2004-06-11 Takeda Chemical Industries Ltd Thienopyridine derivatives, their production and use
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6432433B1 (en) 2000-06-05 2002-08-13 Isp Investments Inc. Liquid biocidal composition of a formaldehyde adduct and an isothiazolone and method of use
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GEP20063908B (en) 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP1443919A4 (en) 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
WO2003055448A2 (en) * 2001-12-21 2003-07-10 Achillion Pharmaceuticals, Inc. Antifungal compositions
US7101676B2 (en) * 2002-01-11 2006-09-05 Douglas Buechter Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA
JP4445753B2 (ja) 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
CN100410388C (zh) * 2002-02-08 2008-08-13 霍夫曼-拉罗奇有限公司 一种鉴定增加骨矿物质密度的化合物的方法
GB0208223D0 (en) * 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2004288831B2 (en) 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
NZ548212A (en) * 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
ZA200605384B (en) * 2003-12-29 2007-10-31 Sepracor Inc Benzo[D]isoxazol-3-OL DAAO inhibitors
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
MX2007013415A (es) * 2005-05-04 2008-01-15 Hoffmann La Roche Compuestos antivirales heterociclicos.
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP2487154B1 (en) 2005-10-31 2013-10-16 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7464565B2 (en) * 2005-11-29 2008-12-16 Maytag Corporation Rapid temperature change device for a refrigerator
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8053603B2 (en) * 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
DK2816024T3 (en) 2006-03-31 2017-10-30 Sunovion Pharmaceuticals Inc CHIRALE AMINER
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
CA2687764A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
MX2009012685A (es) 2007-05-31 2009-12-14 Sepracor Inc Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
PL2170864T3 (pl) 2007-07-17 2012-02-29 Bristol Myers Squibb Co Agoniści receptora gpr119 sprężonego z białkiem g - pirydon
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
AU2008288770B2 (en) 2007-08-23 2014-06-12 Theracosbio, Llc Benzylbenzene derivatives and methods of use
JP2011503081A (ja) 2007-11-01 2011-01-27 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１および／またはＮＦ−κＢ活性の調節剤として有用な非ステロイド性化合物、並びにその使用
KR20100108337A (ko) * 2007-11-15 2010-10-06 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
JP5269087B2 (ja) * 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
BR112012011274A2 (pt) 2009-11-13 2016-04-12 Astrazeneca Uk Ltd formulação de metformina de massa reduzida e sua combinação
CN102711739B (zh) 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US20110257233A1 (en) * 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
CN102971311B (zh) 2010-05-06 2015-07-08 百时美施贵宝公司 作为gpr119调节剂的二环杂芳基化合物
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2600716A4 (en) 2010-08-03 2014-02-19 Beth Israel Hospital METHOD AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES
US9662328B2 (en) 2010-11-29 2017-05-30 National Yang-Ming University Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
TWI445696B (zh) * 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
TR201908247T4 (tr) 2012-11-20 2019-06-21 Lexicon Pharmaceuticals Inc Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
CN103232842B (zh) * 2013-04-15 2015-11-18 山东大学 一种基于聚集诱导荧光增强材料的亚硫酸氢根离子的荧光探针及快速检验试纸
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US20160046651A1 (en) * 2014-07-22 2016-02-18 Washington University Treatment of malaria using inhibitors of the ispd enzyme in the non-mevalonate pathway
CN104230839A (zh) * 2014-09-25 2014-12-24 上海化学试剂研究所有限公司 一种n-取代苯并异噻唑啉酮衍生物的合成方法
US9925190B2 (en) * 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
KR20170138570A (ko) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
CN109715637B (zh) 2016-07-22 2022-04-05 百时美施贵宝公司 葡萄糖激酶激活剂及其使用方法
CN109929806B (zh) 2017-12-19 2020-05-08 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
WO2019126567A1 (en) * 2017-12-22 2019-06-27 Southern Research Institute Substituted heterocyclic-pyridinones as hiv-1 nef-hck inhibitors
AU2019324405B2 (en) 2018-08-23 2022-09-22 Qingdao Rising Biotechnology Co., Ltd. Phenoxy carboxylic acid compounds and medical uses thereof
KR20210065974A (ko) 2018-09-26 2021-06-04 렉시컨 파마슈티컬스 인코퍼레이티드 N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법
CN111253335B (zh) * 2020-03-12 2023-06-06 浙江扬帆新材料股份有限公司 一种n-取代苯并异噻唑啉-3-酮衍生物的新合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE724034C (de) * 1938-11-04 1942-08-17 Algemeene Kunstvezel Mij N V Verfahren zum Erzeugen farbiger Glasfasern
US3012039A (en) * 1958-03-14 1961-12-05 Ici Ltd 2-p-chlorobenzyl-1, 2-benzisothiazolone
US3517022A (en) * 1967-10-03 1970-06-23 Rohm & Haas Certain 2-carbamoyl-1,2-benzisothiazolones
GB1306493A (en) * 1970-04-27 1973-02-14 Sherwin Williams Co Aromatic sulphenamides the preparation thereof and cyclization thereof
US3661974A (en) * 1970-04-27 1972-05-09 Sherwin Williams Co 2-carbalkoxy-phenyl sulfenamides
US3761489A (en) * 1971-12-20 1973-09-25 Sherwin Williams Co Substituted n-alkyl benzisothiazolinones
US4049817A (en) * 1972-08-14 1977-09-20 Sandoz Ltd. Synergistic compositions
US3965107A (en) * 1974-07-08 1976-06-22 Rohm And Haas Company Isothiazolopyridinones
IT1039699B (it) * 1975-07-03 1979-12-10 Prephar Composizione spermicida a base di derivati benzisotiazolici
DE2602643C2 (de) * 1976-01-24 1984-12-20 Bayer Ag, 5090 Leverkusen 1,2-Benzisothiazolinone-3, Verfahren zu ihrer Herstellung sowie Arzneimittel
GB1560726A (en) * 1976-04-28 1980-02-06 Beecham Group Ltd Isothiazolo-pyridines
FR2492376A1 (fr) * 1980-10-17 1982-04-23 Cird Polymethylene-4,5 isothiazoline-4 ones-3, leur procede de preparation et leurs utilisation comme agents bactericides et fongicides
DE3041036A1 (de) * 1980-10-31 1982-06-09 A. Nattermann & Cie GmbH, 5000 Köln Verwendung von benzisothiazolen
US4458942A (en) * 1981-12-07 1984-07-10 American Seating Company Three-quarter fold retracting chair
LU84091A1 (fr) * 1982-04-16 1984-03-02 Oreal Derives n-carbamoyl d'isothiazolo-(5,4b)pyridine one-3,leur procede de preparation et leurs utilisations comme agents bactericides et fongicides
FR2555450B1 (fr) * 1983-11-24 1988-04-01 Oreal Composition anti-acneique contenant en tant que compose actif un derive d'isothiazolo-(5,4b) pyridine one-3
FR2631028B1 (fr) * 1988-05-09 1990-07-13 Cird Adamantyl-2 isothiazoline-4 ones-3, leur procede de preparation et leur utilisation comme agents bactericides et fongicides
US5405851A (en) * 1990-06-19 1995-04-11 Burroughs Wellcome Co. Pharmaceutical compounds
JPH0477476A (ja) * 1990-07-19 1992-03-11 Sankyo Co Ltd 抗潰瘍剤
US5219875A (en) * 1990-11-27 1993-06-15 Rohm And Haas Company Antimicrobial compositions comprising iodopropargyl butylcarbamate and 1,2-benzisothiazolin-3-one and methods of controlling microbes
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
FR2695378B1 (fr) * 1992-09-10 1994-12-02 Aerospatiale Dispositif à sangle pour le maintien temporaire d'objets ensemble.
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли

Also Published As

Publication number Publication date
BG102077A (en) 1998-11-30
DK0828488T3 (da) 2003-05-19
NO975496L (no) 1998-01-22
SK162297A3 (en) 2000-04-10
HUP9900917A3 (en) 2003-04-28
ATE232385T1 (de) 2003-02-15
GT199600026A (es) 1997-11-15
HRP960216B1 (en) 2001-12-31
US5668162A (en) 1997-09-16
CZ373997A3 (cs) 1998-11-11
PE55097A1 (es) 1998-01-16
NZ307023A (en) 2001-03-30
HRP960216A2 (en) 1997-08-31
CO4700292A1 (es) 1998-12-29
EA199700444A1 (ru) 1998-06-25
BG62792B1 (bg) 2000-08-31
PT828488E (pt) 2003-06-30
OA10745A (en) 2002-12-10
EE9700287A (et) 1998-06-15
KR20040004547A (ko) 2004-01-13
US5733921A (en) 1998-03-31
SV1996000033A (es) 1998-01-29
TW418206B (en) 2001-01-11
IL117859A (en) 2000-07-16
MY118452A (en) 2004-11-30
KR19990022132A (ko) 1999-03-25
NO975496D0 (no) 1997-11-28
DE69626203D1 (en) 2003-03-20
EP0828488B1 (en) 2003-02-12
MX9707948A (es) 1997-12-31
UY24244A1 (es) 2001-10-25
CN1185737A (zh) 1998-06-24
WO1996038144A1 (en) 1996-12-05
HN1996000017A (es) 2000-03-24
DE69626203T2 (de) 2003-11-20
IL117859A0 (en) 1996-08-04
HUP9900917A2 (hu) 1999-09-28
CN1114402C (zh) 2003-07-16
JP2002502353A (ja) 2002-01-22
GEP20012375B (en) 2001-03-25
US6133270A (en) 2000-10-17
AU723233B2 (en) 2000-08-24
EA000898B1 (ru) 2000-06-26
AU5577196A (en) 1996-12-18
SV1996000026A (es) 1997-03-05
AR002740A1 (es) 1998-04-29
US5620997A (en) 1997-04-15
ZA964441B (en) 1996-12-10
PL323683A1 (en) 1998-04-14
CA2218253A1 (en) 1996-12-05
EP0828488A1 (en) 1998-03-18

Similar Documents

Publication Publication Date Title
SV1996000033A (es) Isotiazolonas
ES2162284T3 (es) Proceso para la fabricacion de tensioactivos que contienen grupos alquilo de cadena ramificada.
ES2155069T3 (es) Inhibidores de proteasas retrovirales.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
DK1568772T3 (da) Varianter af humant væksthormon
AR003955A1 (es) Derivados de n-(indol-2-carbonil)-glicinamidas, procedimiento para su obtencion y composiciones que los contienen.
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
ES2096560T3 (es) Compuestos de benzocicloheptapiridina sustituida con fluor, composiciones y metodos para uso como compuestos antihistaminicos.
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
MX9207074A (es) Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
ES2147320T3 (es) Derivados de n-(3-benzofuranil)urea.
SE9702773D0 (sv) Novel compounds
AR021695A1 (es) 4,5-pirazinoxindoles, composicion farmaceutica y uso
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
ES2168276T3 (es) 1-arilsulfonil-3-fenil-1,4,5,6-tetrahidropiridazinas.
DK0904282T3 (da) Hidtil ukendte kationiske cholesterylderivater indeholdende cykliske polære grupper
ES2171743T3 (es) Derivados de amidinas e isotioureas como inhibidores de la enzima sintasa de oxido nitrico.
MX9305998A (es) 6-heterociclic-4-amino-1, 3, 4, 5,-tetrahidrobenz[cd] indoles yprocedimiento para su preparacion.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
ES2187783T3 (es) Derivados de indolina utiles como antagonistas del receptor 5-ht-2c.